Niall Martin, Artios CEO
April 7, 2021 02:00 AM EDTUpdated April 9, 03:37 PM
Deals
Discovery

No­var­tis taps DNA dam­age spe­cial­ist Ar­tios in $1.3B dis­cov­ery deal to com­ple­ment grow­ing ra­di­oli­gand port­fo­lio

Kyle Blankenship

With a big Phase III win for its lead ra­di­oli­gand for can­cer last month, No­var­tis is look­ing to quick­ly ramp up its pipeline for those …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times